Associate Director, CMC Drug Substance

• Lead external drug substance development across our portfolio including oversight of CDMOs and strategic technical development relationships
• Provide technical leadership, project management and oversight of drug substance process development and manufacturing activities supporting Recursion's clinical programs
• Ensure delivery of drug substance from external manufacturing campaigns adhering to current quality guidelines and delivery timelines
• Critically analyze process and analytical data to identify and resolve key synthetic challenges during drug substance development
• Participate in developing and extending our CDMO relationships, budget planning and forecasting for drug substance expenditures and achieving our quality requirements

This role advances clinical assets through development to ultimately reach patients in need, contributing to Recursion's mission of decoding biology to radically improve lives through innovative drug discovery.

• Ph.D. in organic chemistry or closely related field with a minimum of 5-8 years experience or M.S. with 8-12 years of experience
• Strong knowledge and experience in small molecule drug substance process development and manufacturing best practices across all phases of drug development
• Prior experience leading external development and CDMO relationships is a plus
• Demonstration of cross-functional understanding related to drug substance development including salt/polymorph screening, phase appropriate analytical development, standard process of drug product development, quality and regulatory affairs
• Well-versed in the latest trends impacting drug substance technology, manufacturing and the outsourcing industry

Estimated annual base range of £84,000 to £98,900 (GBP), plus eligibility for annual bonus and equity compensation, comprehensive benefits package, and values-driven culture emphasizing bold action, deep care, active learning, urgency, ownership, and collaboration.

Recursion is a clinical stage TechBio company leading the space by decoding biology to radically improve lives through its Recursion OS platform, which generates one of the world's largest proprietary biological and chemical datasets using machine learning and massive experimental and computational scale.